Thursday, 2 April 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 02 April 2026
News

Novo's megastar notches a first

Posted 2 April 2026 AM

The TGA has provisionally approved Novo Nordisk’s Wegovy for metabolic dysfunction-associated steatohepatitis (MASH), marking the first approved medication for patients living with the ‘silent disease’ in Australia.

“We're proud to offer the first medication option for Australians living with MASH, who have historically had limited treatment options available,” Novo Nordisk Senior Director of Clinical, Medical and Regulatory, Dr Ana Svensson, said.

To see the whole article, please login

Popular

Aussie pharma exec wins CEO job
Aussie GM exits but where to next?
Pharma unveils a new name
13 pharmas win April PBS listings
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home